GE Healthcare announces the appointment of Gene Cartwright as president of molecular diagnostics; in this new role, Cartwright will lead the development of the in-vitro clinical diagnostics business
"In-vitro diagnostics is an important component for the prediction and early management of disease," said Peter Loescher, president and CEO of GE Healthcare's bio-sciences business.
"We are very excited to have Gene Cartwright join the Bio-Sciences team and to lead this growth engine for the company.
"His successful and extensive experience in diagnostics will be a tremendous asset as we continue to build and invest in the area of molecular diagnostics".
According to Loescher, the molecular diagnostics business is already making inroads to understanding how genomic markers can play a key part in moving from symptom-based to screening-based assessment of congestive heart failure patients.
Additionally, GE Healthcare's two-year collaboration with Oxford University to study colorectal cancer is the first ever to focus on developing a comprehensive disease management program, which will concentrate on improved staging of the disease using imaging and genomic pathology.
GE Healthcare uniquely combines in-vivo imaging, information technologies, analytical instruments and in-vitro diagnostics.
Cartwright, who joins GE from Abbott Laboratories, has more than 20 years of experience in diagnostics.
He began his career at Abbott as a research scientist, ultimately becoming Abbott's vice president of strategic programmes for its molecular diagnostics business.
Cartwright holds a PhD in chemistry from Stanford University.
He will be based in Piscataway, NJ.
